Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

16.93
-1.0250-5.71%
Volume:2.99M
Turnover:51.00M
Market Cap:13.50B
PE:-15.14
High:17.64
Open:17.61
Low:16.80
Close:17.95
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:154.32M
Volume Ratio:1.08
T/O Rate:1.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.43
PE(LYR):-11.72

Loading ...

Summit Therapeutics Says Phase III HARMONi-GI1 Trial of Ivonescimab in Biliary Tract Cancer Shows OS Superiority vs AstraZeneca’s Imfinzi Regimen

Reuters
·
Sep 22

Harmoni-Gi1, a Phase Iii Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to be Showcased in Presidential Symposium at Esmo 2026

THOMSON REUTERS
·
Sep 22

Movement Alert|Summit Therapeutics PLC Falls 5.13% in Regular Trading, Trading at $16.9

Market Focus
·
Sep 21

LEPAS Expands Its Presence Across European Markets, Bringing Elegant Mobility to More Consumers

GlobeNewswire
·
Sep 21

Updated Harmoni Data Presented at Wclc 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

THOMSON REUTERS
·
Sep 15

Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit

MT Newswires Live
·
Sep 15

Big Pharma is Pouring Billions into China's Biotechs

Dow Jones
·
Sep 14

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)

TIPRANKS
·
Sep 14

Summit partner announces updated data from Phase III HARMONi-2 trial

TIPRANKS
·
Sep 13

Summit Therapeutics Advances Ivonescimab Combo Into Pivotal Bladder Cancer Trial

TIPRANKS
·
Sep 12

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
Sep 10

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Sep 09

U.S. Stocks on the MOVE-Meta, Chime Financial, ServiceTitan

Reuters
·
Sep 09

Jefferies Upgrades Summit Therapeutics to "buy", Shares Up

Reuters
·
Sep 09

Summit Therapeutics Inc. : Jefferies Raises to Buy from Hold; Raises Target Price to $25 from $15

THOMSON REUTERS
·
Sep 09

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 08

Shimamura Co Ltd - Notice Concerning Acquisition of Business

Reuters
·
Sep 07

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

Summit Therapeutics Stock (SMMT) Rallies on Positive Clinical Trial Results

TIPRANKS
·
Sep 03

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in Pd-L1-Positive Advanced Nsclc in Harmoni-2 Study Conducted by Akeso in China

THOMSON REUTERS
·
Sep 03